TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Dequalinium Chloride (Fluomizin) vs Oral Metronidazole for the Treatment of Bacterial Vaginosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Premenopausal woman ≥18 years~2. Diagnosis of bacterial vaginosis (all 4 Amsel criteria positive, i.e. 1) greyish white thin discharge, 2) postassium hydroxide (KOH) test or 'fishy' smell, 3) microscopic presence of \> 20% clue cells, 4) vaginal pH \> 4.5)~3. Signed Written Informed Consent to participate in this study~Exclusion Criteria:~1. Pregnancy and/or lactation based on urine Pregnancy test (women with childbearing potential should use any contraception excluding vaginal methods like vaginal ring, etc.)~2. Uterine bleeding (including menstruation) or vaginal bleeding of unknown origin~3. Ulcerations/erosions of vaginal mucosa or cervix uteri~4. Patients with clinical symptoms and findings of Candida vulvovaginitis and/or Aerobic vaginitis~5. Clinically manifest or suspicion of sexually transmitted infections (Neisseria gonorrhoeae, Chlamydia trachomatis, or Trichomonas vaginalis) based on signs, symptoms, and anamnesis~6. Use of any antimicrobial treatment (local or systemic) 14 days before entry the study~7. Use of any vaginal medication or vaginal douching 7 days before entry the study~8. Unwillingness to refrain from alcohol consumption during treatment, and 48 hours after treatment~9. Severe systemic diseases (HIV, cancer, tuberculosis, autoimmune diseases, diabetes mellitus, severe psychiatric conditions, etc.), including diseases treated with immunosuppressive therapies, systemic corticosteroids, or warfarin~10. Known or suspected hypersensitivity to one of the study medications, inclusive of their excipients~11. Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant (including inability to fill-in electronic patient diary)~12. Participation of patient in another investigational drug study concomitantly or within 30 days prior to entry in the study~13. Patient is relative of, or staff directly reporting to, the investigator

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dequalinium chloride (Type: EXPERIMENTAL): Dequalinium chloride 10 mg vaginal tablets
- Metronidazole (Type: ACTIVE_COMPARATOR): Metronidazole 500 mg oral tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Lateral Lymph Node Dissection After Neoadjuvant Chemo-radiation in Advanced Low Rectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed rectal cancer (below the peritoneal reflection) Clinical stage I, II, or III~* No extramesorectal lymph node swelling (shorter diameter is less than 10 mm)~* No invasion to other organ (s)~* PS: 0, 1~* No past history of chemotherapy, pelvic surgery or radiation~* Written informed consent operative criteria:~* Mesorectal excision is performed~* Operative findings:~* Main lesion of the tumor is located at the rectum~* Lower tumor margin is below the peritoneal reflection~* R0 after resection~Exclusion Criteria:~* High rectal cancer~* Multiple cancer patients~* Pregnant patients~* Psychological disorder~* Steroid administration~* Cardiac infarction within six months~* Severe pulmonary emphysema and pulmonary fibrosis~* Doctor's decision for exclusion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- LLND+TME group (Type: EXPERIMENTAL): advanced rectal cancer patients after neoadjuvant chem-radiation with suspicious lateral lymph nodes involvement undergo lateral lymph node dissection and total mesorectal excision(LLND+TME)
- TME group (Type: NO_INTERVENTION): advanced rectal cancer patients after neoadjuvant chem-radiation with suspicious lateral lymph nodes involvement undergo total mesorectal excision (TME)solely, without LLND

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Distal Radius Fracture - Treatment Comparison

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Closed extra-articular distal radius fracture or a minimally displaced intra-articular fracture~* Fracture classified as an AO/OTA A2, A3, C1 or C2 with or without an ulnar styloid fracture~* Must be treated within the first 14 days of injury,~* Male or female greater than or equal to 65 years of age.~* Able to understand the requirements of the study, provide a written informed consent and comply with the study protocol~* Ability to understand and provide written authorization for use and disclosure of personal health information~* Fracture that can be treated closed with or without closed reduction~Exclusion Criteria:~* Concomitant contralateral or ipsilateral upper extremity fractures~* Ipsilateral ulna (excluding styloid) fracture~* Open fracture~* Previous ipsilateral distal radius fracture in the 2 years prior to enrollment with deformity~* Unstable distal radioulnar joint after fracture fixation~* Fractures where the transverse fracture line is less than 10mm from the distal radius joint surface~* Artery or Nerve injury secondary to fracture~* History of alcoholism~* Currently on chemotherapy or radiation therapy~* Currently on worker's compensation~* Rheumatoid arthritis or other inflammatory arthropathies.~* History of chronic pain issues or psychiatric disorder that precludes reliable follow-up.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- WRx™ Intramedullary Nail (Type: EXPERIMENTAL): Patients in this arm of the study will be treated with a minimally invasive WRx™ Intramedullary Nail for their wrist fracture.
- Non surgical treatment (Cast) (Type: ACTIVE_COMPARATOR): Patients in this arm of the study will be treated with a cast for their wrist fracture.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Open Trial Determining Antidepressant Effects of Omega-3 Supplementation During Pregnancy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Women with uncomplicated pregnancy within the 1st or 2nd trimester of pregnancy~2. Score of 10 or greater on the nine item Patient Health Questionnaire (PHQ-9) for depression~Exclusion Criteria:~1. antidepressant use in preceding month~2. use in previous 4 weeks of psychotropic medications other than hypnotics or benzodiazepines in diazepam dose-equivalents greater than or equal to 2mg/day for insomnia~3. Fish allergy~4. initiation of regularly scheduled course of psychotherapy within previous 2 months

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Supplementation (Type: EXPERIMENTAL): Subjects received Omega-3 PUFA supplementation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety of Rabeprazole in Patients Under Multiple Treatments

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients receiving Rabeprazole and a concomitant drug (one or more) such a non-steroidal anti-inflammatory drugs (NSAID), benzodiazepines or corticoids~Exclusion Criteria:~* Pregnant or lactating patients~* Other severe concomitant pathologies~* History or drug or alcohol abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 001 (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Sabril for Complex Partial Seizures in Adult Tolerability Study (TS) Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The patient or patient's legally authorized representative must sign and date the Institutional Review Board approved Informed Consent and HIPPA Authorization Form.~* Male and female patients 18+ years of age with a clinical diagnosis of Tuberous Sclerosis who experience an average of at least three partial seizures every two months, of which one must be a complex partial seizure~* Patient must be on at least one and a maximum of four AEDs. Patient must be on a stable AED dose regimen for at least 30 days prior to screening. Neither a Vagal Nerve Stimulator (VNS) nor the ketogenic diet will count as an AED~* In the investigator's opinion, the patient or caregiver must be able to keep a seizure diary~* An MRI in the last 5 years, or willingness to undergo an MRI as part of the screening process~Exclusion Criteria:~* Cause of patient's seizures is a neurologic disease that is not Tuberous Sclerosis~* Current, clinical diagnosis of a major depressive episode or suicidal ideation~* Patient is taking more than four concurrent AEDs. Note: VNS or ketogenic diet is allowed and will not be counted in the four allowed AEDs~* Patient has a progressive CNS lesion confirmed by magnetic resonance imaging (MRI) or computed tomography (CT) scan~* Patient is currently abusing drugs or alcohol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment with Sabril (vigabatrin) (Type: OTHER): This is a single arm study. All subjects who are eligible for treatment will begin taking vigabatrin (Sabril) during the third month of the study. Treatment will be in accordance with the FDA-approved prescribing information: upward titration will happen at a rate of 500mg per week until subjects reach their maximum tolerated dose, or 3g per day (whichever is lower). This dose may be decreased if needed under the supervision of the study doctor. Subjects who need to lower their dose or who stop taking Sabril will have their dosage decreased at a rate of 1 gm/week for one month under the supervision of the study doctor.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Evaluation of Quality of Life in Patients With Acute Colonic Diverticular Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* imaging-proven colonic diverticular disease~* patient aged \> 18 years old~* Written informed consent obtained~* A colonoscopy showing diverticular disease will be required during the follow-up or before surgical treatment if possible~* Patients undergoing surgical or medical treatment will be enrolled in the registry and undergo a 36-months follow up period.~Exclusion Criteria:~* \< 18 yo

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Diverticular disease (Type: None): All consecutive patients admitted to a Surgical Unit with a diagnosis of left-side colinic diverticulitis will be enrolled in the registry. Patients will be identified through their medical record numbers. One investigator in each center will obtain written informed consent from each patient and keep the patients updated on data collection.~Inclusion criteria: 1) imaging-proven colonic diverticular disease 2) patient aged \> 18 years old; 3) Written informed consent obtained. 4) A colonoscopy showing diverticular disease will be required during the follow-up or before surgical treatment if possible

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5% BAK-Free Fixed Combination) From Prior Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of ocular hypertension, open-angle glaucoma, or pigment dispersion glaucoma in both eyes.~* On a stable IOP-lowering regimen of prostaglandin fixed combination (either Xalacom or Ganfort) within 4 weeks prior to the Screening Visit.~* IOP between 19 and 35 mmHg at any time of day in at least 1 eye.~* Best corrected visual acuity (BCVA) of 6/60 (20/200 Snellen; 1.0 LogMAR) or better in each eye.~* Willing to discontinue the use of all other ocular hypotensive medication(s) prior to receiving the study medication for the entire course of the study.~* Other protocol-defined inclusion criteria may apply.~Exclusion Criteria:~* Known medical history of allergy, hypersensitivity, or poor tolerance to any component of DuoTrav® deemed clinically significant in the opinion of the Principal Investigator.~* Corneal dystrophies in either eye.~* Risk of visual field or VA worsening as a consequence of participation in the study, in the investigator's best judgment.~* Any disease or condition that would preclude the safe administration of a topical beta-blocker, present a special risk to the subject, or interfere with optimal participation in the study.~* Women who are pregnant or lactating.~* Participation in any other investigational study within 30 days prior to the Screening Visit.~* Other protocol-defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DuoTrav (Type: EXPERIMENTAL): Travoprost/Timolol Maleate BAK-Free Fixed Combination, 1 drop self-administered in treated eye(s) once a day for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Bacterial Vaginosis Prior to Active Labor and Infectious Morbidity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women ≤50 years at the time of admission with the ability to give informed con-sent.~* Admission for induction of labor or early spontaneous labor with cervix ≤3 cm.~* Diagnosed with bacterial vaginosis at time of admission or in the week prior to admission if not treated~* Gestational age ≥ 34 weeks~Exclusion Criteria:~* Spontaneous rupture of membranes~* Plan for elective cesarean delivery~* Allergy or contraindications to metronidazole~* Receipt of metronidazole or clindamycin in the admission for delivery for other in-dications.~* Hemodialysis~* Severe liver dysfunction~* Diagnosis of chorioamnionitis at the time of admission

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Control Arm (Type: PLACEBO_COMPARATOR): Placebo tablets oral, 4 tablets once.
- Treatment Arm (Type: ACTIVE_COMPARATOR): Will receive 4 tablets (2g) of metronidazole oral once.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Post Market Study of the 3DKnee™ With E-plus Insert

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject must be a candidate for a total primary knee replacement.~* Subject must have knee joint disease related to degenerative joint disease, including osteoarthritis or traumatic arthritis~* Subject has a BMI ≤ 40.00 kg/m2~* Subject is likely to be available for evaluation for the duration of the study~* Subject is able and willing to sign the informed consent and follow study procedures~* Subject is not pregnant~* Subject must be between age 40 and age 75 at the time of consent~Exclusion Criteria:~* Subject has had a prior total or uni-knee replacement on this knee in the past (no revisions allowed in study)~* Subject has avascular necrosis of the femoral condyles, post-traumatic loss of joint configuration, particularly when there is patellofemoral erosion, dysfunction or prior patellectomy, moderate valgus, varus, or flexion deformities or rheumatoid arthritis~* Subject has an active cancer or is a survivor for \<5 years except for squamous cell or basal cell skin cancer~* Subject has a chronic disease(s) where, in the opinion of the investigator, the disease will interfere with the patient's ability to follow the protocol~* Subject is currently a documented substance abuser (alcohol or other addictions)~* Subject has an infection, or history of infection (within the last 3 months), acute or chronic, local or systemic~* Subject has a history of muscular, neurological or vascular deficiencies which compromise the affected extremity~* Subject has a BMI \> 40.00 kg/m2~* Subject has loss of ligamentous structures~* Subject has high levels of physical activity and is unwilling to modify levels of physical activity commensurate with recommendations~* Subject has a mental condition that may interfere with the subject's ability to give an informed consent or willingness to fulfill the study requirements (i.e., severe mental retardation such that the Subject cannot understand the informed consent process, global dementia, prior strokes that interfere with the Subject's cognitive abilities, senile dementia, and Alzheimer's Disease)~* Subject is a prisoner~* Subject is pregnant~* Subject has known materials sensitivity (to metals)~* Subject is younger than 40 years (\<40) or older than 75 years (\>75) at the time of consent

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 3DKnee™ with e-plus Insert (Type: None): Subjects who meet the indications for use criteria for the 3DKnee™ System with vitamin E UHMWPE tibial inserts (VE) and who are candidates for a primary knee arthroplasty.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: uPAR PET/CT in Radium-223-dichloride Treatment of Patients With Metastatic Castration-resistant Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Metastatic castration resistant prostate cancer~* Approved to receive Radium-223 therapy~* Written and oral consent~Exclusion Criteria:~* Lack of communication skills~* Other known malignant disease~* Known allergy towards IMP~* Severe claustrophobia~* If a participant exhibits allergic reaction i the IMP, the participant will be excluded from further participation in the study

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- uPAR PET/CT (Type: EXPERIMENTAL): Injection of 68Ga-NOTA-AE105 followed by PET/CT scan. Administration will be performed twice in approximately 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Monetary Incentives for Primary Care Physicians on Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Physicians participating in the COFRASA cohort study~* informed consent~Exclusion Criteria:~- None

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- inclusion with financial motivation (Type: EXPERIMENTAL): 75 euros for each patient included
- no incentive (Type: NO_INTERVENTION): no incentive

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues